Thromb Haemost 2013; 109(03): 564-565
DOI: 10.1160/TH12-08-0548
Letters to the Editor
Schattauer GmbH

Revival of PFA-100 – how far is it useful for the monitoring of ADP receptor antagonists?

Jacek Golanski
1   Department of Haemostasis and Haemostatic Disorders, Medical University of Lodz, Lodz, Poland
,
Kamila Syska
1   Department of Haemostasis and Haemostatic Disorders, Medical University of Lodz, Lodz, Poland
,
Cezary Watala
1   Department of Haemostasis and Haemostatic Disorders, Medical University of Lodz, Lodz, Poland
› Author Affiliations
Further Information

Publication History

Received: 03 August 2012

Accepted after major revision: 30 January 2012

Publication Date:
29 November 2017 (online)

 

 
  • References

  • 1 Mallouk N, Labruyere C, Reny JL. et al. Prevalence of poor biological response to clopidogrel: a systematic review. Thromb Haemost 2012; 107: 494-506.
  • 2 Golanski J, Pluta J, Baraniak J. et al. Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists--in vitro experience. Clin Chem Lab Med 2004; 42: 25-29.
  • 3 Siller-Matula JM, Delle-Karth G, Lang IM. et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost 2012; 10: 529-542.
  • 4 Koessler J, Kobsar AL, Rajkovic MS. et al. The new INNOVANCE(R) PFA P2Y cartridge is sensitive to the detection of the P2Y receptor inhibition. Platelets 2011; 22: 19-25.
  • 5 Edwards A, Jakubowski JA, Rechner AR. et al. Evaluation of the INNOVANCE PFA P2Y test cartridge: sensitivity to P2Y(12) blockade and influence of anticoagulant. Platelets 2012; 23: 106-115.
  • 6 Kinsella JA, Tobin WO, Cox D. et al. Prevalence of Ex Vivo High On-treatment Platelet Reactivity on Antiplatelet Therapy after Transient Ischemic Attack or Ischemic Stroke on the PFA-100((R)) and VerifyNow((R)). J Stroke Cerebrovasc Dis. 2012 epub ahead of print
  • 7 Jang J, Lim J, Chang K. et al. A comparison of INNOVANCE(R) PFA P2Y and VerifyNow P2Y12 assay for the assessment of clopidogrel resistance in patients undergoing percutaneous coronary intervention. J Clin Lab Anal 2012; 26: 262-266.